CDCB has strategically invested in technology modernization, development of new data pipelines, new trait discovery, and increased outreach – along with delivering genetic evaluations and stewarding the National Cooperator Database.
Within this Activity Report, CDCB Chair Lindsey Worden outlines the 2024-26 CDCB Strategic Plan, and CEO João Dürr describes the actions to execute the strategic vision.
Key progress points from October 2023 to September 2024: